Bliss GVS Pharma rose 0.39% to Rs 181 at 10:30 IST on BSE after the company said that its board approved hiking foreign portfolio investors limits in the firm to 74% from 24%.
The announcement was made after market hours yesterday, 25 February 2019.Meanwhile, the S&P BSE Sensex was down 336.05 points, or 0.93% to 35,877.33.
On the BSE, 1.19 lakh shares were traded in the counter so far compared with average daily volumes of 2.37 lakh shares in the past two weeks. The stock had hit a high of Rs 182 and a low of Rs 177.20 so far during the day.
The stock hit a 52-week high of Rs 224.70 on 25 April 2018. The stock hit a 52-week low of Rs 125 on 6 December 2018.
On a consolidated basis, net profit of Bliss GVS Pharma rose 44.20% to Rs 25.84 crore on 12.53% rise in net sales to Rs 220.43 crore in Q3 December 2018 over Q3 December 2017.
Bliss GVS Pharma is a pharmaceutical company. It develops, manufactures and markets pharmaceutical formulations.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app